Skip to main content
. Author manuscript; available in PMC: 2023 Dec 1.
Published in final edited form as: Gynecol Oncol. 2022 Oct 20;167(3):404–413. doi: 10.1016/j.ygyno.2022.08.021

Fig. 1.

Fig. 1.

Distribution of PFS outcomes in ARIEL3 patients. (A) Frequencies of PFS outcomes in rucaparib-arm patients (pie chart) and distribution of PFS in the exceptional benefit, short-term, and all others subgroups in the rucaparib arm (histogram). (B) Frequencies of PFS outcomes in placebo-arm patients (pie chart) and distribution of PFS in the exceptional benefit, short-term, and all others subgroups in the placebo arm (histogram). Two patients who were included in the rucaparib short-term subgroup had a relapse on the first scan, but the gap in scan scheduling was longer than expected (at 6 months and 9 months after their first dose of rucaparib; protocol deviation). PFS, progression-free survival.